Published in Gene Therapy Weekly, February 14th, 2002
The research collaboration will help advance preclinical development of INGN 241, (adenoviral-mda7), Introgen's novel gene-based drug designed to kill cancer cells without harming normal cells.
The grant, titled "Gene Therapy for Human Malignant Melanoma," is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.